Dr. Xian Shen, M.D., Ph.D.

Position:

· Chief Surgeon, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Wenzhou Medical University

· Professor of Medicine, The First Affiliated Hospital of Wenzhou Medical University

Institution:

· The First Affiliated Hospital of Wenzhou Medical University

· The Second Affiliated Hospital of Wenzhou Medical University

Specialty:

· Gastrointestinal Surgery

Education:

· 2001 - 2003: M.D., Naval Medical University, The People’s Republic of China

· 2003 - 2006: Ph.D., Naval Medical University, The People’s Republic of China

Work Experience:

· 1998 - 2008: Attending Doctor, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University

· 2006 - 2009: Lecturer, The First Affiliated Hospital of Wenzhou Medical University

· 2008 - 2014: Associate Chief Surgeon, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University

· 2009 - 2015: Vice Professor of Medicine, The First Affiliated Hospital of Wenzhou Medical University

· 2014 - 2016: Chief Surgeon, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University

· 2016 - 2022: Chief Surgeon, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Wenzhou Medical University

Honors and Awards:

· 10000 talent program in Zhejiang province

· High-level talents of health innovation in Zhejiang province

Professional Memberships and Societies:

· Party Secretary of The First Affiliated Hospital of Wenzhou Medical University

· Leader of Clinical Nutriology (Pillar Science Program) in Zhejiang province

· Vice-chairman of Parenteral and Enteral Nutrition Society, Chinese Medical Association

· Chairman-elect of Zhejiang Parenteral and Enteral Nutrition Society

· Vice-chairman of Professional Committee of Nutrition Physicians, Zhejiang Medical Doctors Association

· Vice-chairman of Surgery Branch of Zhejiang Medical Association

Grant Review:

· National Natural Science Foundation of China

· Natural Science Foundation of Guangdong Province

· Natural Science Foundation of Heilongjiang Province

Reviewer for Journals:

· Cell Death & Disease

· Oncogene

· Frontiers in Oncology

· Frontiers in Nutrition

· Cancer Medicine

· World Journal of Gastroenterology

Grant Funding:

1. Natural Science Foundation, 32070151 (P.I. Xian Shen)

o “Study on molecular mechanism and effect of HCMV latent-related UL138 gene inducing immunogenic cell death in gastric cancer”

o Period: 2021-2024

o ¥580,000 total direct costs

2. Natural Science Foundation, 31670922 (P.I. Xian Shen)

o “Study on molecular mechanism and effect of HCMV latent-related UL138 gene inducing immunogenic cell death in gastric cancer”

o Period: 2017-2020

o ¥600,000 total direct costs

3. Natural Science Foundation, 31670922 (P.I. Xian Shen)

o “Construction and immunogenicity of gastrointestinal tumor-associated antigen epitope chimeric virus-like particle vaccine”

o Period: 2015-2018

o ¥800,000 total direct costs

4. Provincial and Ministry Jointly Built Project, WKJ-ZJ-1806 (P.I. Xian Shen)

o “Individual precision therapy of gastric cancer patients based on a three-dimensional culture of in vitro tumor tissue”

o Period: 2018-2021

o ¥500,000 total direct costs

5. Major Research of Zhejiang Province, 2021C03120 (P.I. Xian Shen)

o “Research on new immunotherapy technology for malignant Tumor: Research and application of new immunotherapy technology for gastric cancer mediated by controlled cell pyrosis”

o Period: 2021-2024

o ¥2600,000 total direct costs

6. Zhejiang Academician Workstation (P.I. Xian Shen)

o “Construction and promotion of a new model for early screening of gastric cancer”

o Period: 2019-2021

o ¥300,000 total direct costs

7. International Cooperation Projects (P.I. Xian Shen)

o “2020 provincial international science and technology cooperation base”

o Period: 2020-present

o ¥2000,000 total direct costs

8. Wenzhou high-level innovation team (P.I. Xian Shen)

o “Innovative Team of Precise Diagnosis and Treatment and Transformation Application of Gastric Cancer [ (Science and Technology)]”

o Period: 2021-2023

o ¥1000,000 total direct costs

Research Directions and Accomplishments:

1. Sarcopenia: Our team has proposed diagnostic criteria for sarcopenia applicable to the Asian population (Ann Surg Oncol, Medicine, cited more than 300 times) and established the first online muscle tissue automatic segmentation platform in China. The precision nutrition assessment and perioperative pre-rehabilitation system based on sarcopenia has been promoted and applied in 16 A-list hospitals in China, reducing postoperative complications and unplanned readmissions, and shortening postoperative hospitalization.

2. Immunotherapy: Our team first proposed PD-L1 expression combined with multiple biomarkers (SETD2) as the standard for treatment selection of PD-1 or PD-L1 blockade (BMJ, 192 citations; NPJ Precis Oncol). We completed PD-L1 detection in more than 2000 patients and proposed the prognostic model of immune gene expression in Asian gastric cancer patients, guiding immunotherapy for gastric and colorectal cancer patients.

3. Human Cytomegalovirus (HCMV) and Gastric Cancer: Our team discovered that HCMV is a common pathogen of gastrointestinal tumor infection. We proposed a new adjuvant therapy for gastric cancer based on antiviral principles and conducted a single-center phase I trial of Hum Vacc Immunother, significantly extending progression-free survival time. We also constructed optical-controlled pyrotopia neoantigen-reactive T cells, showing promising application prospects.

PUBLICATIONS

A. Peer-reviewed Original Articles

[1] Chen S, Shen X. Long noncoding RNAs: functions and mechanisms in colon cancer[J]. Molecular cancer, 2020, 19(1): 1-13.

[2] Sun L, Wang Y, Zhang X, et al. Bio-inspired self-replenishing and self-reporting slippery surfaces from colloidal co-assembly templates[J]. Chemical Engineering Journal, 2021, 426: 131641.

[3] Chen X, Zhao Y, Luo W, et al. Celastrol induces ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells[J]. Theranostics, 2020, 10(22): 10290.

[4] Xu K, Zhan Y, Yuan Z, et al. Hypoxia induces drug resistance in colorectal cancer through the HIF-1α/miR-338-5p/IL-6 feedback loop[J]. Molecular Therapy, 2019, 27(10): 1810-1824.

[5] Shen X, Fu W, Wei Y, et al. TIGIT-Fc Promotes Antitumor Immunity[J]. Cancer Immunology Research, 2021, 9(9): 1088-1097.

[6] Zhang M, Chen X, Li C, et al. Charge-reversal nanocarriers: An emerging paradigm for smart cancer nanomedicine[J]. Journal of Controlled Release, 2020, 319: 46-62.

[7] Liu R, Tang J, Ding C, et al. The depletion of ATM inhibits colon cancer proliferation and migration via B56γ2-mediated Chk1/p53/CD44 cascades[J]. Cancer Letters, 2017, 390: 48-57.

[8] Zhuge W, Chen R, Vladimir K, et al. Costunolide specifically binds and inhibits thioredoxin reductase 1 to induce apoptosis in colon cancer[J]. Cancer letters, 2018, 412: 46-58.

[9] Hu Y, Chen C, Tong X, et al. NSUN2 modified by SUMO-2/3 promotes gastric cancer progression and regulates mRNA m5C methylation[J]. Cell death & disease, 2021, 12(9): 1-13.

[10] Lu M, Zhao B, Liu M, et al. Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy[J]. NPJ precision oncology, 2021, 5(1): 1-6.

[11] Ye L, Zhang T, Kang Z, et al. Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer[J]. Frontiers in immunology, 2019: 2368.

[12] Zhang F-M, Chen X-L, Wu Q, et al. Development and validation of nomograms for the prediction of low muscle mass and radiodensity in gastric cancer patients[J]. The American Journal of Clinical Nutrition, 2021, 113(2): 348-358.

[13] Zhang F-M, Zhang X-Z, Shi H-P, et al. Comparisons and Impacts of the Basic Components of Sarcopenia Definition and Their Pairwise Combinations in Gastric Cancer: A Large-Scale Study in a Chinese Population[J]. Frontiers in nutrition, 2021: 774.

[14] Jin J, Shen X, Chen L, et al. TMPRSS4 promotes invasiveness of human gastric cancer cells through activation of NF-κB/MMP-9 signaling[J]. Biomedicine & Pharmacotherapy, 2016, 77: 30-36.

[15] Dai D, Yin Y, Hu Y, et al. Tumor RNA-loaded nanoliposomes increases the anti-tumor immune response in colorectal cancer[J]. Drug Delivery, 2021, 28(1): 1548-1561.

[16] Pan C, Zhang T, Li S, et al. Hybrid nanoparticles modified by hyaluronic acid loading an HSP90 inhibitor as a novel delivery system for subcutaneous and orthotopic colon cancer therapy[J]. International Journal of Nanomedicine, 2021, 16: 1743.

[17] Zhao B, Gao M, Zhao H, et al. Efficacy and safety profile of avelumab monotherapy[J]. Critical reviews in oncology/hematology, 2021, 166: 103464.

[18] Chen S, Chen C, Hu Y, et al. Three-Dimensional Ex Vivo Culture for Drug Responses of Patient-Derived Gastric Cancer Tissue[J]. Frontiers in oncology, 2021, 10: 3275.

[19] Ye S, Hu Y, Chen C, et al. The Human Cytomegalovirus US31 Gene Predicts Favorable Survival and Regulates the Tumor Microenvironment in Gastric Cancer[J]. Frontiers in oncology, 2021, 11.

[20] Pan B, Zhang W, Chen W, et al. Establishment of the Radiologic Tumor Invasion Index Based on Radiomics Splenic Features and Clinical Factors to Predict Serous Invasion of Gastric Cancer[J]. Frontiers in oncology, 2021: 3138.

[21] Mao C, Ma L, Huang Y, et al. Immunogenomic Landscape and Immune-Related Gene-Based Prognostic Signature in Asian Gastric Cancer[J]. Frontiers in Oncology, 2021, 11.

[22] Chen L, Li W-F, Wang H-X, et al. Curcumin cytotoxicity is enhanced by PTEN disruption in colorectal cancer cells[J]. World Journal of Gastroenterology: WJG, 2013, 19(40): 6814.

[23] Hu C, Lin F, Zhu G, et al. Abnormal hypermethylation of promoter region downregulates chemokine CXC ligand 14 expression in gastric cancer[J]. International Journal of Oncology, 2013, 43(5): 1487-1494.

[24] Wang S-L, Zhuang C-L, Huang D-D, et al. Sarcopenia adversely impacts postoperative clinical outcomes following gastrectomy in patients with gastric cancer: a prospective study[J]. Annals of surgical oncology, 2016, 23(2): 556-564.

[25] Xie W, Chen C, Han Z, et al. CD2AP inhibits metastasis in gastric cancer by promoting cellular adhesion and cytoskeleton assembly[J]. Molecular carcinogenesis, 2020, 59(4): 339-352.

[26] Sun X, Xu J, Chen X, et al. Sarcopenia in Patients With Normal Body Mass Index Is an Independent Predictor for Postoperative Complication and Long‐Term Survival in Gastric Cancer[J]. Clinical and Translational Science, 2021, 14(3): 837-846.

[27] Xu J, Wen J, Li S, et al. Immune-Related Nine-MicroRNA Signature for Predicting the Prognosis of Gastric Cancer[J]. Frontiers in Genetics, 2021, 12.

[28] Zhang F-M, Ma B-W, Huang Y-Y, et al. Laparoscopic colorectal cancer surgery reduces the adverse impacts of sarcopenia on postoperative outcomes: a propensity score-matched analysis[J]. Surgical Endoscopy, 2020, 34(10): 4582-4592.

[29] Huang D-D, Chen X-X, Chen X-Y, et al. Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer: a prospective study[J]. Journal of cancer research and clinical oncology, 2016, 142(11): 2347-2356.

[30] Liu X, Lin K, Huang X, et al. Overexpression of the human cytomegalovirus UL111A is correlated with favorable survival of patients with gastric cancer and changes T-cell infiltration and suppresses carcinogenesis[J]. Journal of cancer research and clinical oncology, 2020, 146(3): 555-568.

[31] Yu J, Zhuang C, Shao S, et al. Risk factors for postoperative fatigue after gastrointestinal surgery[J]. The Journal of surgical research, 2015, 194(1): 114-9.

[32] Zhuang C, Huang D, Pang W, et al. Sarcopenia is an Independent Predictor of Severe Postoperative Complications and Long-Term Survival After Radical Gastrectomy for Gastric Cancer: Analysis from a Large-Scale Cohort[J]. Medicine, 2016, 95(13): e3164.

[33] Huang D, Zhou C, Wang S, et al. Impact of different sarcopenia stages on the postoperative outcomes after radical gastrectomy for gastric cancer[J]. Surgery, 2017, 161(3): 680-693.

[34] Zhang L, Guo G, Xu J, et al. Human cytomegalovirus detection in gastric cancer and its possible association with lymphatic metastasis[J]. Diagnostic microbiology and infectious disease, 2017, 88(1): 62-68.

[35] Chen X, Mao C, Wu R, et al. Use of the combination of the preoperative platelet-to-lymphocyte ratio and tumor characteristics to predict peritoneal metastasis in patients with gastric cancer[J]. PloS one, 2017, 12(4): e0175074.

[36] Zhou C, Zhang F, Zhang F, et al. Sarcopenia: a new predictor of postoperative complications for elderly gastric cancer patients who underwent radical gastrectomy[J]. The Journal of surgical research, 2017, 211: 137-146.

[37] Xu J, Zhao Z, Ye L, et al. Prognostic significance of Daxx NCR (Nuclear/Cytoplasmic Ratio) in gastric cancer[J]. Cancer medicine, 2017, 6(9): 2063-2075.

[38] Wang S, Ma L, Chen X, et al. Impact of visceral fat on surgical complications and long-term survival of patients with gastric cancer after radical gastrectomy[J]. European journal of clinical nutrition, 2018, 72(3): 436-445.

[39] Ye X, Ji Y, Ma B, et al. Comparison of three common nutritional screening tools with the new European Society for Clinical Nutrition and Metabolism (ESPEN) criteria for malnutrition among patients with geriatric gastrointestinal cancer: a prospective study in China[J]. BMJ open, 2018, 8(4): e019750.

[40] Zhang W, Lin J, Chen W, et al. Sarcopenic Obesity Is Associated with Severe Postoperative Complications in Gastric Cancer Patients Undergoing Gastrectomy: a Prospective Study[J]. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract, 2018, 22(11): 1861-1869.

[41] Ji W, Chandoo A, Guo X, et al. Enhanced recovery after surgery decreases intestinal recovery time and pain intensity in patients undergoing curative gastrectomy[J]. Cancer management and research, 2018, 10: 3513-3520.

[42] Chen X, Li B, Ma B, et al. Sarcopenia is an effective prognostic indicator of postoperative outcomes in laparoscopic-assisted gastrectomy[J]. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2019, 45(6): 1092-1098.

[43] Lin J, Zhang W, Chen W, et al. Muscle Mass, Density, and Strength Are Necessary to Diagnose Sarcopenia in Patients With Gastric Cancer[J]. The Journal of surgical research, 2019, 241: 141-148.

[44] Zhuang C, Shen X, Huang Y, et al. Myosteatosis predicts prognosis after radical gastrectomy for gastric cancer: A propensity score-matched analysis from a large-scale cohort[J]. Surgery, 2019, 166(3): 297-304.

[45] Chen X, Zeng Y, Huang Y, et al. Preoperative Cachexia predicts poor outcomes in young rather than elderly gastric cancer patients: a prospective study[J]. Cancer management and research, 2019, 11: 8101-8110.

[46] Zhou C, Cheng Y, Xie L, et al. Metabolic Syndrome, as Defined Based on Parameters Including Visceral Fat Area, Predicts Complications After Surgery for Rectal Cancer[J]. Obesity surgery, 2020, 30(1): 319-326.

[47] Chen X, Zhang X, Ma B, et al. A comparison of four common malnutrition risk screening tools for detecting cachexia in patients with curable gastric cancer[J]. Nutrition (Burbank, Los Angeles County, Calif.), 2020, 70: 110498.

[48] Wang X, Sun J, Zhang W, et al. Use of radiomics to extract splenic features to predict prognosis of patients with gastric cancer[J]. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, 46: 1932-1940.

[49] Xu L, Zhang H, Shi M, et al. Metabolic syndrome-related sarcopenia is associated with worse prognosis in patients with gastric cancer: A prospective study[J]. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, 46(12): 2262-2269.

[50] Xu L, Huang Z, Zhang H, et al. Impact of Preoperative Short-Term Parenteral Nutrition Support on the Clinical Outcome of Gastric Cancer Patients: A Propensity Score Matching Analysis[J]. JPEN. Journal of parenteral and enteral nutrition, 2021, 45(4): 729-737.

[51] Ni Z, Xing D, Zhang T, et al. Tumor-infiltrating B cell is associated with the control of progression of gastric cancer[J]. Immunologic research, 2021, 69(1): 43-52.

[52] Yu Y, Zhang J, Ni L, et al. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer[J]. Human vaccines & immunotherapeutics, 2021: 1-11.

[53] Xu L, Shi M, Huang Z, et al. Impact of malnutrition diagnosed using Global Leadership Initiative on Malnutrition criteria on clinical outcomes of patients with gastric cancer[J]. JPEN. Journal of parenteral and enteral nutrition, 2022, 46(2): 385-394.

[54] Chen F F, Zhang F Y, Zhou X Y, et al. Role of frailty and nutritional status in predicting complications following total gastrectomy with D2 lymphadenectomy in patients with gastric cancer: a prospective study[J]. Langenbecks Arch Surg, 2016, 401(6): 813-22.

[55] Ma B W, Chen X Y, Fan S D, et al. Impact of sarcopenia on clinical outcomes after radical gastrectomy for patients without nutritional risk[J]. Nutrition, 2019, 61: 61-66.

[56] Chen X, Zhang W, Sun X, et al. Metabolic syndrome predicts postoperative complications after gastrectomy in gastric cancer patients: Development of an individualized usable nomogram and rating model[J]. Cancer Med, 2020, 9(19): 7116-7124.

[57] Sun J, Yang H, Cai W, et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer[J]. BMC Gastroenterol, 2022, 22(1): 26.

B. Patents

1. The utility model relates to a portable patient file storage box. Primary Inventor: Xian Shen; Additional Inventors: Zhang liang; Chen Wenjing. Sun Xiangwei; Low can

2. A method of preparation and application of hydrogel microspheres with an optical-thermal response. Primary Inventor: Xian Shen; Additional Inventors: Shou Xin, Zhao Yuanjin, Sun Weijian, Wang Yuetong, Shang Luoran

3. A method of preparation and application of Antibacterial hydrogel-loaded microspheres in cell amplification. Primary Inventor: Xian Shen; Additional Inventors: Xian Shen, Shou Xin, Zhao Yuanjin, Shang Luoran, Wang Yuetong, SunWeijian;

4. A method of preparation and application of optical-heat-driven drugs to release hydrogel microspheres. Primary Inventor: Xian Shen; Additional Inventors: ShouXin; Zhao Yuanjin; Sun Weijian; Wang Yuetong; But, no other

5. Sarcopenia online assessment platform V1.0. Primary Inventor: Xian Shen

6. L3 level muscle fat automatic segmentation system. Primary Inventor: Xian Shen

Contact Information:

· Tel: +86(577) 88002593

· Fax: +86(577) 5557 9555

· Email: 13968888872@163.com